LouisFehrenbacherMD

Oncology • Vallejo, CA

Hematologist/Oncologist at t Kaiser Permanente in Vallejo

Join to view full profile

Dr. Fehrenbacher is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fehrenbacher's full profile

Already have an account?

Office
975 Sereno Dr
Vallejo, CA 94589

Summary

Louis Fehrenbacher, MD, is a retired hematology oncology specialist based in Vallejo, CA. He completed his medical degree at the David Geffen School of Medicine at UCLA in 1973, followed by a residency in Internal Medicine at Kaiser Permanente (KP) Northern California and a fellowship in Hematology and Medical Oncology at the University of California, San Francisco. He provided clinical hematology and oncology care at KP Vallejo for 40 years and was the Chief on Oncology there from 1981 until 2010. He was the medical director of the Kaiser Permanente Northern California Oncology Clinical Trials Program from 1993 to 2018, and the first NCI NCORP PI for KP from 2014 to 2018. Dr. Fehrenbacher has authored numerous publications on cancer treatment and clinical trial eligibility and has been involved in multiple clinical trials, including studies on breast cancer, lung cancer, and leukemia. His work in oncology includes significant contributions to understanding treatment efficacy and safety.

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1976 - 1978
Kaiser Permanente Northern California (San Francisco)Residency, Internal Medicine, 1973 - 1976
David Geffen School of Medicine at UCLAClass of 1973

Certifications & Licensure

CA State Medical License 1974 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Clinical Trials

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma Start of enrollment: 2001 Jun 01
Completed
Phase 2
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jul 19
COMPLETED
PHASE3
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Start of enrollment: 2006 Jul 01
Completed
Phase 3
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Jul 28
ACTIVE_NOT_RECRUITING
PHASE3
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Dec 01
Completed
Phase 2
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
ACTIVE_NOT_RECRUITING
PHASE3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Apr 15
Completed
Phase 3
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
ACTIVE_NOT_RECRUITING
PHASE3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Start of enrollment: 2010 Mar 15
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Start of enrollment: 2010 Jun 01
Completed
Phase 3
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Start of enrollment: 2010 Sep 15
Terminated
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32 Start of enrollment: 2011 Jul 01
Unknown status
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Start of enrollment: 2011 May 24
ACTIVE_NOT_RECRUITING
PHASE3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Start of enrollment: 2012 Feb 01
Completed
Phase 3
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer Start of enrollment: 2012 May 16
Completed
Not Applicable
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
ACTIVE_NOT_RECRUITING
PHASE3
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia Start of enrollment: 2017 Sep 26
ACTIVE_NOT_RECRUITING
Join now to see all

Publications & Presentations

PubMed

2 citations
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.
Priya Rastogi, Hanna Bandos, Peter C Lucas, Laura J van 't Veer, Jia-Perng J Wei
Journal of Clinical Oncology. 2024-10-20
3 citations
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner
Clinical Cancer Research. 2024-05-01
10 citations
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, Barry C Lembersky, Jong-Hyeon Jeong
Journal of the National Cancer Institute. 2023-11-08

Press Mentions

Adjuvant Trastuzumab Did Not Improve Outcomes for Patients with HER2-Low Breast CancerDecember 6th, 2017
Experimental Targeted Immunotherapy Drug Performs Better Than Chemotherapy for Treatment of Advanced Lung Cancer Kaiser Permanente Clinical Trial Also Shows Genetic Biomarkers Can Help Predict Who Responds Best to TherapyMarch 15th, 2016